Prostamax
Prostamax is a short-chain peptide bioregulator from the Khavinson family, studied for its tissue-specific effects on the prostate and urogenital system. In animal and Russian clinical literature it is associated with normalized prostate tissue architecture, reduced inflammatory signaling, and improved urinary function. It is used in research contexts as a short-course subcutaneous peptide rather than a daily long-term therapy.
Adult men in a research context interested in prostate and urogenital tissue support, particularly around age-related prostate changes or chronic prostatitis models.
Prostamax is one of the short synthetic peptide bioregulators developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, part of a class derived from or modeled on prostate tissue extracts (the parent extract being marketed in Russia as Prostatilen/Prostamax). It is a very short peptide (reported as a tetrapeptide such as Lys-Glu-Asp-Pro), small enough to be proposed to enter cells and interact with DNA.
The proposed mechanism is epigenetic: these peptides are thought to bind specific DNA/histone regions and modulate the expression of tissue-specific genes, effectively nudging prostate cells toward a more youthful, differentiated expression pattern. Preclinical work in aged and prostatitis-model rodents reports reduced prostate inflammation, decreased swelling, more normal cellular architecture, and favorable shifts in androgen-receptor-related gene expression. Russian clinical experience with the peptide/extract lineage describes improvements in urinary flow and prostate symptom scores.
Importantly, the strongest clinical evidence belongs to the original tissue extract, not the isolated synthetic peptide, and there is no independent Western replication or controlled human trial of synthetic Prostamax itself. Prostamax is not approved by the FDA, is sold for research use only, and is not a treatment for prostatitis, BPH, or any prostate condition; anyone considering it should do so only under qualified physician guidance and with appropriate prostate evaluation.
Subcutaneous injection, typically 500 mcg to 1 mg once daily for a short 10-20 day course, repeated every 4-6 months; a conservative starting dose is 500 mcg/day. Documented human dosing is limited, so the lower end is the safest starting point.
Functional changes (urinary flow, IPSS-type symptom scores) in the Russian literature are typically described 4-6 weeks after completing a course, not during it.
Sometimes combined with other Khavinson-family bioregulators (e.g. Epitalon) in longevity research stacks; otherwise typically run standalone.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.